Addressing Gaps in Canadian Pharmacare
According to Morgan and Boothe (2016), Canada's Medicare system is the only one among the developed countries that has universal public health insurance but does not also have universal prescription drug coverage. The amount of out-of-pocket (OOP) spending can become a great burden on Canadians, as private insurance “only composes approximately 34.3% of expenditures,” (Hennessey et al., 2016); and in Ontario, 1 in 3 people do not have employer-provided health benefits to begin with (Barnes, 2015). Cost-related non-adherence to prescription drugs is associated with households with low income, which can lead to poorer, avoidable outcomes such as increased hospital admissions, worsening disease, and an
…show more content…
Not following prescriptions as ordered causes more stress on the health care system because it increases visits to physicians’ offices and emergency departments that may have been avoidable if the medication was covered for all Canadians (Lexchin, 2017). There are various political barriers to implementing a universal drug coverage plan in Canada. Primarily the federal government’s Patented Medicine Prices Review Board of Canada (PMPRBC). This board controls prescription and non-prescription prices by making comparisons of across seven selected Organisation of Economic Co-Operation and Development (OECD) countries (Tang, Ghali, & Manns, 2014). However the OECD countries have high costs for medications, four of which have the most expensive prices in the world, therefore increasing Canadian prices. According to Morgan and Boothe (2016), another barrier to universal drug coverage stems from “pharmacare’s initially low place on the policy agenda” (p. 249). Healthy public policy development requires synergy between the public, policy makers, and institutions alike. If universal drug coverage has “less attention than other health policy debates” a political change is less likely to occur (p. 251).
A few key stakeholders include government, physicians, pharmaceutical and insurance companies, nurses and patients. The government plays a significant role in the provision of prescription drug pricing by “establishing
Portability means that Canadians have access to public health insurance even when they travel within Canada or internationally. Accessibility means that no Canadian will be discriminated against on the basis of income, age, health, etc. These conditions lay the foundation for Canada’s health care system. Additionally the Canada Health Act aims to protect, promote, and restore the physical and mental well being of Canadians and focuses on delivering medically necessary procedures in terms of need and not ability to pay. (“Canada Health Act,” 1984) Many Canadians take great pride in the notion of a universal healthcare and the idea of not having to pay upfront fees for medical services but in reality this notion is overstated and ignores the disadvantages of the healthcare sector. In fact in the latest Commonwealth Study, Canada was compared to eleven other major industrialized countries around the world, and was actually ranked second to last, just above the U.S.A (Flood, 2014) Canadians are often caught up in the idea that we have a great health care system by comparing it the U.S.A’s, but simply being better than our neighbouring country is not an
In Canada the services, medication and hospital fee are controlled by the government, this created a better outcome for the security of the citizen. This regulation can lead to major saving in term of the GDP per capita paid by the government in this regard. The government negotiates drug prices so by doing that prices are more affordable for the people. It’s not necessary the uses of co-pays and deductible, but if any type of charged for any reason this can still be a dissent price by the patient. As result of this Canadian are proud and feel secured by the contribution of the social
Today, Canada is the only industrialized nation without a national pharmacare plan (“Campaign for a National Drug Plan” 1). Currently, each province has its own pharmacare plan and this creates differences in medication prices across the nation. Price depends on drug efficacy, how commonly the drug is used, and to what extent the provincial government decides to subsidize the drug. Overall, drug coverage in Canada depends on a person’s age, income, and the province they live in. Today, one in ten Canadians cannot afford the medications that their doctors prescribe (“Pharmacare 2020” 2). Their lack of
The current system is inefficient, inequitable and unsustainable in the long run because: (1) it is unable to accommodate for the entire Canadian population; (2) it requires Canadians to pay a disproportionate amount of their income to access medications; and (3) governments are unable to contain the drug cost increases (5). Therefore two recommended reforms are described in order to achieve the goal of accessibility and equity.
According to Morgan and Boothe (2016), Canada's medicare system is the only one among developed countries that has universal public health insurance but does not also have universal prescription drug coverage. The amount of out-of-pocket (OOP) spending is an immense burden for many Canadians, accounting for 34.3% of private expenditures, (Hennessey et al., 2016); and in Ontario, one in three people do not have employer-provided health insurance (Barnes & Anderson, 2015). Moreover, “cost-related non-adherence to prescription drugs is associated with low-income households”, which may lead to poorer avoidable outcomes such as: increasing hospital admissions, worsening disease, and growing overall
The article deals with the trichotomy that presents itself in Canada, Insured America, and Uninsured America. The article is an analysis of the differences between all three with more focus on how uninsured America is separate from the other two. The focus is on the aged old question of “Whose residents have better access to health care, the United States’ or Canada’s?”(699). Morgan and Kennedy state that the Joint Canada U.S. Survey of Health data showed that despite major differences in their health systems, most Canadians and Americans get the care they need. The problem is that a certain group, uninsured America, are much more likely to report serious access barriers. About “one-third of currently or recently uninsured Americans”, aged
There is plenty of evidence to validate that many Canadians are incorrect in believing that they have “the best healthcare system in the world”. Spending on healthcare in Canada continues to outpace the government spending program in growth and is limiting public investments in other areas that would make for an overall more effective society (Daniel Muzyka). Canada is the 10th highest spender, spending an average of $2,600 per Canadian per year. Recent studies by Brett Skinner have looked at trends in the annual growth rates for provincial healthcare expenditures and total government revenue. “He found that if recent trends persist, provincial government spending on healthcare will consume more than half of total revenues from all sources in six of 10 provinces by the year 2020” (Neil Stuart).
One important issue that plagues the Canadian health system is the affordability of prescription drugs, which arises from the medication not being covered under Canada’s current universal health care system (Parliament of Canada). The prescription drugs are either paid out of pocket, or covered a certain percentage depending on their private insurance or benefits given by their profession. For those who cannot afford the medication it causes a dilemma, choosing to take on a financial burden for the sake of their own treatment and without taking the needed treatment the disease may get worse. Since it is out-of-the-pocket the wealthy can obtain the medication, while the poor are handcuffed to do so, therefore making this a financial and an equity
In Canada, drug spending is considered to be the second largest spending category of healthcare ("Protecting Canadians from Excessive Drug Prices", 2017). Ever since Medicare was established in Canada, health expensive has increased to about 16% ("Protecting Canadians from Excessive Drug Prices", 2017). Canada is found to pay way more on prescription drugs than compared to other developed countries ("Protecting Canadians from Excessive Drug Prices", 2017). Not only does the high expense affect the consumer, but it also limits the access to creating new medicines as well as having less resource in other areas in the healthcare field ("Protecting Canadians from Excessive Drug Prices", 2017). As of January 2016, the provincial, federal, and territorial ministers have planned to work together in order to improve the accessibility, affordability, and
In Canada different public prescription drug programs are based on the assumptions that the working class of Canada does
Canada’s health care system “can be described as a publicly-funded, privately-provided, universal, comprehensive, affordable, single-payer, provincially administered national health care system” (Bernard, 1992, p.103). Health care in Canada is provincial responsibility, with the Canada Health act being a federal legislation (Bernard, 1992, p. 102). Federal budget cuts, has caused various problems within Medicare such as increased waiting times and lack of new technology. Another problem with Medicare is that The Canada Heath Act does not cover expenditures for prescriptions drugs. All these issue has caused individuals to suggest making Medicare privatized. Although, Canada’s health care system consists of shortcomings, our universal
In this essay, federal drug policy, and its correlation with the shortage of drugs in Canada, will be considered. In particular, the disruption of drug supply will be discussed, with a specific focus on drug supply within the province of Ontario. A discussion will ensue surrounding drug pricing and policy, and the ways in which these frameworks can ultimately serve to affect the efficacy of medical treatment and the safety of patients. In addition, the paper will focus on the accountability of multiple stakeholders, at both the federal and provincial levels, in terms of supplying medically necessary drugs to Canadians. This analysis will encompass the dominant role played by pharmaceutical actors in Canada. Finally, conclusion will be drawn which take account of existing federal and provincial programs that aim to address drug shortages and the recommendations on comprehensive and appropriate drug funding.
The lessons of Canadian national health insurance are as straightforward as they are neglected (Oberlander, 2016). Having a single government-operated insurance plan greatly reduces administrative costs and complexity. It concentrates purchasing power to reduce prices, enables budgetary control over health spending, and guarantees all legal residents, regardless of age, health status, income, or occupation, coverage for core medical services. Canadian Medicare charges patients no copayments or deductibles for hospital or physician services. Controlling medical spending does not, the Canadian experience demonstrates, require cost sharing that deters utilization. The Canadian system is hardly perfect. All countries struggle with tensions among cost, access, and quality; at times, Canada has grappled with fiscal pressures, wait lists for some services, and public dissatisfaction. Yet its problems pale in comparison to those in the United
In this essay, federal drug policy, and its correlation with the shortage of drugs in Canada, will be considered. In particular, the disruption of drug supply will be considered, with a specific focus on drug supply within the province of Ontario. A discussion will ensue surrounding drug pricing and policy, and the ways in which these frameworks can ultimately serve to affect the efficacy of medical treatment and the safety of patients. Finally, the paper will focus on the accountability of multiple stakeholders, at both the federal and provincial levels, in terms of supplying medically necessary drugs to Canadians. This analysis will encompass the dominant role played by pharmaceutical actors in Canada. Finally, conclusions will be drawn
The rise in costs of prescription medicines affects all sectors of the health care industry, including private insurers, public programs, and patients. Spending on prescription drugs continues to be an important health care concern, particularly in light of rising pharmaceutical costs, the aging population, and increased use of costly specialty drugs. In recent history, increases in prescription drug costs have outpaced other categories of health care spending, rising rapidly throughout the latter half of the 1990s and early 2000s. (Kaiseredu.org, 2012).